Table
2: Univariate
analysis of patient’s characteristics for overall survival
No. of patients |
Median survival (months) |
5-year survival (%) |
P |
|
Age at primary (years) <50 >50 |
21 12 |
81.2 30.9 |
73.0 25.0 |
0.1623 |
Age at LM (years) <50 >50 |
15 18 |
72.8 57.0 |
76.0 38.9 |
0.0986 |
ER* status positive negative |
14 14 |
66.3 40.9 |
65.1 35.7 |
0.3075 |
PgR† status positive negative |
11 16 |
64.8 41.9 |
77.8 31.3 |
0.0937 |
HER2‡ status positive(2+, 3+) negative(-, +) |
7 14 |
67.7 47.9 |
50.0 59.7 |
0.8186 |
Timing of detection of BCLM synchronus metachronous |
6 27 |
32.6 74.7 |
33.3 58.7 |
0.2302 |
No. of BCLM solitary >1 |
13 20 |
77.6 58.0 |
90.9 33.0 |
0.2005 |
Maximal BCLM size (mm) <30 >30 |
17 16 |
73.8 55.2 |
61.4 45.7 |
0.7731 |
Extrahepatic metastases ator before liver surgery Yes No |
13 20 |
41.4 83.5 |
27.5 68.0 |
0.0153 |
*estrogen-receptor; †progesterone-receptor; ‡human epidermal
growth factor receptor 2